ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Beyond Joint Hypermobility: Investigatin…

Beyond Joint Hypermobility: Investigating Bladder Dysfunction in Hypermobile Ehlers‐Danlos Syndrome

Neurourology and Urodynamics·June 18Open Access
Urology & NephrologyLimited evidenceHypermobile Ehlers-Danlos SyndromeLower Urinary Tract SymptomsPelvic Floor DysfunctionRetrospective Chart ReviewBeta-3 Adrenergic AgonistPelvic Floor Physical TherapyAdult

Summary

View source

What was studied

This retrospective chart review evaluated lower urinary tract symptoms (LUTS) and urodynamic (UDS) findings in 27 adult patients with confirmed hypermobile Ehlers-Danlos Syndrome (hEDS) who underwent video urodynamics at a single tertiary-care center between 2022 and 2025.

Key findings

LUTS were common: urinary frequency (74.1%), weak stream (51.8%), nocturia (48.1%), bladder pain (33.3%), recurrent UTIs (25.9%), and incontinence (14.8%). Urodynamics showed **no** detrusor overactivity, stress urinary incontinence, or compliance abnormalities; pelvic floor dysfunction (dyssynergic EMG during voiding) was found in 18.5% (n=5). Pelvic floor physical therapy was the most recommended treatment, followed by beta-3 agonists.

Study limitations

- Very small sample (n=27) from a single tertiary-care center limits generalizability. - Retrospective design introduces selection and ascertainment bias. - Cohort was 92.6% female and 92.6% white, limiting applicability to other demographics.

Clinical implications

In hEDS patients with LUTS, urodynamics are unlikely to reveal intrinsic bladder pathology—pelvic floor dysfunction and neurologic contributors appear more relevant. Prioritize pelvic floor physical therapy evaluation before escalating to pharmacologic or invasive bladder-directed interventions.

Related Questions

Explore related topics

What urodynamic findings are expected in connective tissue disorders like Ehlers-Danlos Syndrome?How should pelvic floor dysfunction be evaluated and treated in hEDS patients with urinary symptoms?Are beta-3 agonists effective for overactive bladder symptoms in patients with connective tissue disorders?

Publication Details

Year
2026
Journal
Neurourology and Urodynamics
Sample Size
n=27
Source
View article
Keep scrolling
More content below.
Up Next